Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895982 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
A Phase 2 study, sponsored by BioNTech SE.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT04895982 is a Phase 2 study that has completed, run by BioNTech SE. The registered enrollment target is 124 participants.
The verdict
NCT04895982, a Phase 2 study, has completed, sponsored by BioNTech SE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico.
Interventions
- BIOLOGICAL BNT162b2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2021-10-15 |
| Est. Completion | 2023-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04895982
The ClinicalTrials.gov registry entry for NCT04895982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BNT162b2 is the first listed.
NCT04895982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04895982 about?
NCT04895982 is a clinical study titled "Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years". This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, an...
What is the current status of trial NCT04895982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2021-10-15. Estimated completion is 2023-07-23.
What interventions are being tested in trial NCT04895982?
The interventions under investigation include: BNT162b2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04895982?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.